Articles

Multiple founders from Linear Capital's portfolio companies have been selected for 36Kr's "2023 Sci-Tech Innovators" list.

Multiple founders from Linear Capital's portfolio companies have been selected for 36Kr's "2023 Sci-Tech Innovators" list.

Last week, 36Kr released its "2023 Sci-Tech Innovators" list. In its introduction, 36Kr highlighted the opportunities and divides it discovered through interviews and research on scientist entrepreneurship: "After two months of open nominations, we still found a group of innovators willing to stay in the arena and attempt to bridge that divide. As representatives of technological innovation grown from Chinese soil, their existence continues to point toward the many possibilities of translating research into commerce." Among them, WeiJian Technology, a portfolio company of Linear Capital,

Linear Capital partner Songyan Huang has once again been selected for Cyzone's "40 Under 40 Investors" list.

Linear Capital partner Songyan Huang has once again been selected for Cyzone's "40 Under 40 Investors" list.

Last week, *Cyzone* (创业邦) released its 2023 "40 Under 40" list — "40 Investors Under 40." This marks the 11th year Cyzone has published the ranking. According to Cyzone, the list was compiled over two months of applications, research, and interviews, evaluating candidates across four dimensions: investment experience, performance, exits, and industry influence. **Songyan Huang, Partner at Linear Capital, was named to this year's "40 Under 40," following his selection in 2022**

A Visit to a Dalton Venture Family Company | Heyuan Bio's Lulu Lyu: China's Homegrown CAR-T Therapy Is About to Become Reality, Bringing New Hope for Relapsed or Refractory Acute Lymphoblastic Leukemia Patients

A Visit to a Dalton Venture Family Company | Heyuan Bio's Lulu Lyu: China's Homegrown CAR-T Therapy Is About to Become Reality, Bringing New Hope for Relapsed or Refractory Acute Lymphoblastic Leukemia Patients

"After nearly five years, He Yuan Bio's first core product, inaticabtagene autoleucel injection, has treated more than 100 Chinese patients in clinical studies for acute lymphoblastic leukemia — representing the largest accumulated dataset to date on CD19 CAR-T clinical safety and efficacy in a Chinese patient population."